NCT06266364

Targeted Plasticity Therapy for PTSD

Targeted Plasticity Therapy for the Treatment of Post-Traumatic Stress Disorder

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The University of Texas at Dallas · Academic / Other
• Sex: All
• Age: 22 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

Objectives of this study are to provide continued safety assessment for the ReStore system, and to gain further estimates of the effect size of Vagus Nerve Stimulation (VNS) therapy with Prolonged Exposure Therapy (PE) compared to PE with placebo (sham) stimulation in participants with posttraumatic stress disorder (PTSD)

Detailed description

A prospective, multi-center, randomized, controlled, blinded trial of participants implanted with the ReStore Device for VNS Therapy. In double-blinded Phase 1, after implantation, participants will be randomized to either active VNS stimulation or sham VNS stimulation, accompanying PE therapy twice weekly for 7 weeks (12 in-office sessions, Phase 1). The therapist and the participant will be blinded of the group assignment. Following completion of Phase 1, all participants undergo two mid-therapy assessments and then advance to the open-label Phase 2. In open-label Phase 2, all participants will receive up to an additional 12 sessions of PE therapy paired with active VNS stimulation, regardless of their prior assignment in Phase 1. Post-therapy assessments will be performed 1 day, 1 month, and 6 months following the completion of the final session of PE in Phase 2. During the in-office sessions, the therapist will use a secure smart device to deliver stimulation and record audio of the session for use during homework sessions. The smart device will automatically trigger VNS during audio homework sessions at the same times that the therapist delivered VNS during the corresponding in-office session. Long-term assessment of safety will be performed up to four times annually for up to 2 years following the date of implant or until the device is FDA approved when possible. Safety assessment will only report on the presence of the implanted, non-active device and/or participant status during this period. Participants who experience a serious device-related adverse event will be removed from the identified risk but will continue to be monitored for 2 years or longer if the event has not resolved.

Conditions

• PTSD, Post Traumatic Stress Disorder

Interventions

Type	Name	Description
DEVICE	Active VNS stimulation	The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1
DEVICE	Sham VNS stimulation	The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1

Timeline

• Start date: 2024-12-30
• Primary completion: 2027-09-01
• Completion: 2028-06-01
• First posted: 2024-02-20
• Last updated: 2025-07-03

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated device study